Key Highlights

  • Shares trading up 1.57% pre-market, adding $0.18 to reach $11.64
  • Move comes as investors digest recent 13F filings showing mixed institutional activity
  • Sei Investments boosted its stake by 69.1% in the first quarter, while Bank of America trimmed its position by 14.2%
  • Stock remains anchored near recent levels following its July 30 fiscal fourth-quarter Earnings beat
  • Fiscal Q4 adjusted EPS of $0.09 topped the $0.06 estimate, with Revenue of $225.3 million topping the $212.35 million consensus
  • Fiscal 2027 revenue guidance of $880 million to $885 million implies only modest core growth of roughly 3%

Shares Little Changed Amid Mixed Institutional Activity

Neogen (NASDAQ:NEOG) shares are trading little changed in pre-market trading Thursday, up 1.57% to $11.64, as investors digest recent 13F filings showing mixed institutional activity. Sei Investments boosted its stake by 69.1% in the first quarter, while Bank of America trimmed its position by 14.2%, reflecting divided sentiment consistent with the stock's consensus 'Hold' rating.

Neogen Corporation, headquartered in Lansing, Michigan, is a global leader in developing, manufacturing, and Marketing diagnostic and safety solutions for the food and animal health industries. Operating through its Food Safety and Animal Safety segments, the company provides test kits and related products to detect foodborne pathogens, toxins, allergens, drug residues, and sanitation issues, as well as veterinary instruments, pharmaceuticals, vaccines, and genomics testing services for livestock and companion animals, serving customers in more than 140 countries.

Shares Remain Anchored Near Recent Levels

The stock remains anchored near recent levels following its July 30 fiscal fourth-quarter earnings beat, when adjusted EPS of $0.09 topped the $0.06 estimate and revenue of $225.3 million topped the $212.35 million consensus. Fiscal 2027 revenue guidance of $880 million to $885 million implies only modest core growth of roughly 3%, keeping analyst enthusiasm tempered despite Piper Sandler's recent price target increase to $13.

Conclusion

Neogen's modest pre-market gain reflects investors digesting mixed institutional positioning rather than any fresh company-specific catalyst, with the stock anchored near recent levels roughly two weeks after its fiscal fourth-quarter earnings beat. With fiscal 2027 guidance implying only modest core growth, the stock's next moves will likely depend on whether the company can accelerate growth beyond the low-single-digit pace currently reflected in its outlook.